FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2074023030> ?p ?o ?g. }

• W2074023030 endingPage "435" @default.
• W2074023030 startingPage "425" @default.
• W2074023030 abstract "Introduction Thrombin is a multifunctional trypsin-like serine protease that plays key roles in coagulation and thrombogenesis. HY023016, a novel Dabigatran prodrug, is an oral direct thrombin inhibitor. The purpose of this study was to compare the anti-thrombotic activities and haemorrhagic effects of HY023016 with Dabigatran etexilate and tetramethylpyrazine in several animal thrombosis models. Methods To investigate drug exposure, liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was used to determine the pharmacokinetic profile of HY023016. After single intragastric administrations of HY023016, Dabigatran etexilate or tetramethylpyrazine, the anti-thrombotic activities were evaluated through rabbit jugular vein thrombosis model, rat inferior vena cava thrombosis model, ex vivo rabbit platelet aggregation assay, in vivo rabbit coagulation assay, and direct thrombin binding assay. Meanwhile, we evaluated the effect of HY023016 on expression of tissue factor (TF) by RT-PCR. Rabbit cuticle bleeding assay and mouse tail bleeding assay were applied to evaluate the effects of HY023016 on haemorrhage. Results Pharmacokinetic parameters indicated that HY023016 can convert to Dabigatran and tetramethylpyrazine. Our studies showed that HY023016 was able to significantly inhibit thrombus formation in a dose-dependent manner in rabbit and rat models (P < 0.05). Similarly, it was able to dose-dependently inhibit thrombin- or ADP-induced platelet aggregation, prolonging the activated partial thromboplastin time (APTT) and prothrombin time (PT), inhibiting the activity of thrombin and inhibiting thrombin- or ADP-induced expression of TF (P < 0.05 or 0.01). Dabigatran etexilate was also able to dose-dependently and significantly inhibit thrombus formation (P < 0.01) but was unable to affect ADP-induced platelet aggregation and expression of TF. In contrast, tetramethylpyrazine could only exhibit mild antithrombotic activity compared with HY023016 and Dabigatran etexilate (P < 0.05). HY023016 could prolong bleeding time (P < 0.001), but the prolongations were significantly less than Dabigatran etexilate (P < 0.05). Conclusion HY023016 showed thrombosis-inhibition activities comparable to those of Dabigatran etexilate, but better than those of tetramethylpyrazine. The attendant bleeding risk of HY023016 was lower than Dabigatran etexilate in rabbits and mice." @default.
• W2074023030 created "2016-06-24" @default.
• W2074023030 creator A5013117076 @default.
• W2074023030 creator A5025612679 @default.
• W2074023030 creator A5032986788 @default.
• W2074023030 creator A5070973535 @default.
• W2074023030 creator A5077834898 @default.
• W2074023030 creator A5082975698 @default.
• W2074023030 creator A5084879504 @default.
• W2074023030 creator A5090079560 @default.
• W2074023030 creator A5091841028 @default.
• W2074023030 date "2013-05-01" @default.
• W2074023030 modified "2023-09-27" @default.
• W2074023030 title "Antithrombotic activity of HY023016, a novel Dabigatran prodrug evaluated in animal thrombosis models" @default.
• W2074023030 cites W164295419 @default.
• W2074023030 cites W1878559559 @default.
• W2074023030 cites W1967889750 @default.
• W2074023030 cites W1974741225 @default.
• W2074023030 cites W1982179895 @default.
• W2074023030 cites W1985416926 @default.
• W2074023030 cites W1990912219 @default.
• W2074023030 cites W2000438765 @default.
• W2074023030 cites W2002761976 @default.
• W2074023030 cites W2015236573 @default.
• W2074023030 cites W2018129107 @default.
• W2074023030 cites W2018777979 @default.
• W2074023030 cites W2020412451 @default.
• W2074023030 cites W2041254215 @default.
• W2074023030 cites W2043153375 @default.
• W2074023030 cites W2058927570 @default.
• W2074023030 cites W2078328099 @default.
• W2074023030 cites W2079096912 @default.
• W2074023030 cites W2118092611 @default.
• W2074023030 cites W2164306500 @default.
• W2074023030 cites W2164564948 @default.
• W2074023030 cites W2170251955 @default.
• W2074023030 cites W4236825038 @default.
• W2074023030 cites W4294216491 @default.
• W2074023030 cites W1969771080 @default.
• W2074023030 doi "https://doi.org/10.1016/j.thromres.2013.03.004" @default.
• W2074023030 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23535565" @default.
• W2074023030 hasPublicationYear "2013" @default.
• W2074023030 type Work @default.
• W2074023030 sameAs 2074023030 @default.
• W2074023030 citedByCount "11" @default.
• W2074023030 countsByYear W20740230302015 @default.
• W2074023030 countsByYear W20740230302016 @default.
• W2074023030 countsByYear W20740230302017 @default.
• W2074023030 countsByYear W20740230302018 @default.
• W2074023030 countsByYear W20740230302020 @default.
• W2074023030 countsByYear W20740230302022 @default.
• W2074023030 crossrefType "journal-article" @default.
• W2074023030 hasAuthorship W2074023030A5013117076 @default.
• W2074023030 hasAuthorship W2074023030A5025612679 @default.
• W2074023030 hasAuthorship W2074023030A5032986788 @default.
• W2074023030 hasAuthorship W2074023030A5070973535 @default.
• W2074023030 hasAuthorship W2074023030A5077834898 @default.
• W2074023030 hasAuthorship W2074023030A5082975698 @default.
• W2074023030 hasAuthorship W2074023030A5084879504 @default.
• W2074023030 hasAuthorship W2074023030A5090079560 @default.
• W2074023030 hasAuthorship W2074023030A5091841028 @default.
• W2074023030 hasConcept C108215921 @default.
• W2074023030 hasConcept C126322002 @default.
• W2074023030 hasConcept C142724271 @default.
• W2074023030 hasConcept C150903083 @default.
• W2074023030 hasConcept C185592680 @default.
• W2074023030 hasConcept C186738567 @default.
• W2074023030 hasConcept C202751555 @default.
• W2074023030 hasConcept C204787440 @default.
• W2074023030 hasConcept C207001950 @default.
• W2074023030 hasConcept C26291073 @default.
• W2074023030 hasConcept C2776301958 @default.
• W2074023030 hasConcept C2776710957 @default.
• W2074023030 hasConcept C2777292125 @default.
• W2074023030 hasConcept C2778208062 @default.
• W2074023030 hasConcept C2778261982 @default.
• W2074023030 hasConcept C2778382381 @default.
• W2074023030 hasConcept C2778810321 @default.
• W2074023030 hasConcept C2779161974 @default.
• W2074023030 hasConcept C2780077467 @default.
• W2074023030 hasConcept C2781362458 @default.
• W2074023030 hasConcept C55493867 @default.
• W2074023030 hasConcept C71924100 @default.
• W2074023030 hasConcept C86803240 @default.
• W2074023030 hasConcept C89560881 @default.
• W2074023030 hasConcept C98274493 @default.
• W2074023030 hasConceptScore W2074023030C108215921 @default.
• W2074023030 hasConceptScore W2074023030C126322002 @default.
• W2074023030 hasConceptScore W2074023030C142724271 @default.
• W2074023030 hasConceptScore W2074023030C150903083 @default.
• W2074023030 hasConceptScore W2074023030C185592680 @default.
• W2074023030 hasConceptScore W2074023030C186738567 @default.
• W2074023030 hasConceptScore W2074023030C202751555 @default.
• W2074023030 hasConceptScore W2074023030C204787440 @default.
• W2074023030 hasConceptScore W2074023030C207001950 @default.
• W2074023030 hasConceptScore W2074023030C26291073 @default.
• W2074023030 hasConceptScore W2074023030C2776301958 @default.
• W2074023030 hasConceptScore W2074023030C2776710957 @default.

• next